KYTX Kyverna Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1994702 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY2.0%
TTM EPS YoY26.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-110.7%
ROA-83.8%
ROIC (approx.)-105.6%
Asset turnover—
Leverage & solvency
Liabilities / assets29.7%
Debt / equity0.19x
Current ratio7.01x
Interest coverage-64.90x
Cash quality & payout
Operating cash flow / net income0.96x
Accruals ratio-3.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 |
|---|---|---|---|
| Income statement | |||
| Revenue | — | — | — |
| R&D expense | $133.72M | $112.47M | $49.92M |
| SG&A expense | $36.11M | $30.13M | $12.48M |
| Operating income | -$169.83M | -$142.60M | -$62.41M |
| Interest expense | $489,000 | $142,000 | $187,000 |
| Income tax | $0 | $0 | $0 |
| Net income | -$161.31M | -$127.48M | -$60.37M |
| EBITDA | -$168.03M | -$140.47M | -$60.70M |
| EPS (basic) | -3.64 | -3.33 | -89.61 |
| EPS (diluted) | -3.64 | -3.33 | -89.61 |
| Weighted avg. shares (diluted) | 44.26M | 38.33M | 673,622 |
| Balance sheet | |||
| Cash & equivalents | $124.09M | $96.62M | $34.65M |
| Short-term investments | $155.16M | $189.36M | $22.90M |
| Current assets | $282.95M | $290.60M | $60.66M |
| PP&E, net | $1.55M | $3.35M | $2.33M |
| Total assets | $293.83M | $304.64M | $75.19M |
| Current liabilities | $36.49M | $33.76M | $19.86M |
| Long-term debt | $24.74M | — | — |
| Total debt | $24.74M | — | — |
| Total liabilities | $61.55M | $38.06M | $26.02M |
| Shareholders' equity | $232.28M | $266.59M | -$13.14M |
| Net debt | -$99.35M | — | — |
| Shares outstanding | 60.39M | 43.21M | 1.25M |
| Cash flow statement | |||
| Operating cash flow | -$153.71M | -$114.25M | -$52.41M |
| Capital expenditure | $5,000 | $2.21M | $621,000 |
| Free cash flow | -$153.72M | -$116.45M | -$53.03M |
| Investing cash flow | $40.02M | -$160.90M | -$8.79M |
| Financing cash flow | $141.17M | $337.11M | $58.12M |
| Depreciation & amortization | $1.80M | $2.13M | $1.71M |
| Stock-based compensation | $10.08M | $8.36M | $2.22M |
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.